Abemaciclib is effective against pancreatic cancer cells and synergizes with HuR and YAP1 inhibition

Mutation or promoter hypermethylation of CDKN2A is found in over 90% of pancreatic ductal adenocarcinomas (PDAC) and leads to loss of function of cell cycle inhibitors p16 (INK4A) and p14 (ARF) resulting in unchecked proliferation. The CDK4/6 inhibitor, abemaciclib (Lilly, IN) has nanomolar IC(50)’s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Res
Main Authors: Dhir, Teena, Schultz, Christopher W., Jain, Aditi, Brown, Samantha Z., Haber, Alex, Goetz, Austin, Xi, Chunhua, Su, Gloria H., Xu, Liang, Posey, James, Jiang, Wei, Yeo, Charles J., Golan, Talia, Pishvaian, Michael J., Brody, Jonathan R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6794000/
https://ncbi.nlm.nih.gov/pubmed/31383722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-19-0589
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados